All In Biotech

Drug Trial Radar · NCT04838444

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

363

Actual

Start

Apr 2, 2021

Primary completion

Mar 3, 2023

Study completion May 2031

Sponsor

Lead sponsor
Valneva Austria GmbHIndustry
Sponsor type
Industry
First posted
Apr 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).

Conditions

  • Chikungunya Virus Infection

Interventions

  • VLA1553Biological

    Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Seroresponse Levels Post-vaccination. (Defined as µPRNT50 ≥150)Time frame: Year 2

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Accelerated Enrollment Solutions (AES)

    Phoenix, Arizona

  • Velocity Clinical Research

    Hallandale, Florida

  • Accelerated Enrollment Solutions (AES)

    Chicago, Illinois

  • Alliance for Multispecialty Research (AMR)

    Lexington, Kentucky

  • Velocity Clinical Research

    Grand Island, Nebraska

  • Velocity Clinical Research

    Omaha, Nebraska

  • Alliance for Multispecialty Research (AMR)

    Knoxville, Tennessee

  • Velocity Clinical Research

    Austin, Texas

  • Velocity Clinical Research

    West Jordan, Utah

  • Allliance for Multispecialty Research (AMR)

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.